mechanism of action semaglutide (Wegovy®) Incretin-based therapy of metabolic disease

Article summary AI generated The dysregulation of the glutathione (GSH) redox system in cancer cells presents both a challenge for conventional therapies and an opportunity for innovative treatment strategies

Mortality and maximal exercise capacity at 24 months were the primary endpoints

There is one Phase I trial registered as NCT02637284 in 2015, intended to enrol forty-two participants, which was subsequently cancelled with no published results [7]

Without insurance a GLP-1 prescription at a pharmacy can cost upwards of $1000 a month

Physician oversight ensures that treatment is individualized, that monitoring is appropriately structured, and that any emerging adverse effects are identified and addressed promptly

10.1016/j.pnpbp.2023.110915 16 KapsiS.KatsantoniS.DrigasA